A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
==== Magnetic resonance and radio-frequency pulses ==== A perturbation of nuclear spin orientations from equilibrium will occur only when an oscillating magnetic field is applied whose frequency νrf sufficiently closely matches the Larmor precession frequency νL of the nuclear magnetization. The populations of the spin-up and -down energy levels then undergo Rabi oscillations, which are analyzed most easily in terms of precession of the spin magnetization around the effective magnetic field in a reference frame rotating with the frequency νrf. The stronger the oscillating field, the faster the Rabi oscillations or the precession around the effective field in the rotating frame. After a certain time on the order of 2–1000 microseconds, a resonant RF pulse flips the spin magnetization to the transverse plane, i.e. it makes an angle of 90° with the constant magnetic field B0 ("90° pulse"), while after a twice longer time, the initial magnetization has been inverted ("180° pulse"). It is the transverse magnetization generated by a resonant oscillating field which is usually detected in NMR, during application of the relatively weak RF field in old-fashioned continuous-wave NMR, or after the relatively strong RF pulse in modern pulsed NMR.
== Safety Profile == Amarasate has been well tolerated in human trials, with no serious adverse events reported. Mild gastrointestinal symptoms such as bloating or nausea have occasionally been observed, typically resolving without intervention. The extract is derived from a food source (hops) traditionally used in brewing and is generally recognized as safe (GRAS) by the FDA for use in dietary supplements.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Sources: en.wikipedia.org
The hydroxide ion OH−, a well known base, is here acting as the conjugate base of the acid water. Acids and bases are thus regarded simply as donors and acceptors of protons respectively. A broader definition of acid dissociation includes hydrolysis, in which protons are produced by the splitting of water molecules. For example, boric acid (B(OH)3) produces H3O+ as if it were a proton donor, but it has been confirmed by Raman spectroscopy that this is due to the hydrolysis equilibrium:
In 2014, Guinness released Guinness Blonde, a lager brewed in Latrobe, Pennsylvania using a combination of Guinness yeast and American ingredients. When Guinness opened their new brewery in Baltimore, Maryland in August 2018 they recreated "Blonde" to "Baltimore Blonde" by adjusting the grain mixture and adding Citra for a citrus flavour and removed the Mosaic hops. Guinness released a lager in 2015 called Hop House 13. It was withdrawn from sale in the UK in May 2021, following poor sales, but remains on sale in Ireland. In 2020, Guinness announced the introduction of a zero alcohol canned stout, Guinness 0.0. It was withdrawn from sale almost immediately after launch, due to contamination. It was relaunched in 2021 starting with pubs in mid July with cans following in late August. In September 2021, Guinness Nitrosurge was released in pint sized cans which contain no widget. Similar to the Surger, nitrogen is activated using ultrasonic frequencies. Nitrosurge uses a special device attached to the top of the can which activates the nitrogen as it is being poured.
=== Shafer presidency === At first, the expired contract Shafer inherited did not seem an intractable problem. In December 1991, PEF members ratified a contractual change to their health plan which was seen as a referendum on Shafer's leadership. But negotiations for the expiring PEF contract soon broke down, a legislative fact-finding panel was imposed on the talks, and the state proposed eliminating nearly 14,000 public sector jobs. Finally, the governor set a June 25 deadline for resolving any contract talks. PEF held out. But when other unions settled their contracts, PEF wanted the same deal and didn't get it. The state legislature adjourned without enacting any PEF contract, although it was on the verge of passing a law requiring binding arbitration between the state and PEF. The lack of a contract created a crisis for many PEF members. Nearly 153,000 PEF workers and their family members lost their prescription drug, dental care, and vision care benefits in September 1992. The governor urged both sides to bargain as the benefits crisis worsened, although a state judge later ordered the benefits restored through the end of calendar year 1992. As the state laid off public workers, PEF's membership dropped from 59,000 to 55,000 members, depriving the union of $1 million in dues revenue. Vacant positions on PEF's staff were eliminated or went unfilled (angering members, who felt the brunt of the grievance and service cuts), and officers took salary cuts.
Sources: en.wikipedia.org
In October 2008, Pierre-Emmanuel Thomann wrote in Défense nationale et sécurité: "This conflict is, above all, the multipolar world's first war. [...] The conflict between Russia and Georgia is larger than a local territorial affair and will have repercussions on a regional and worldwide scale. [...] Its presence in South Ossetia, close to the territorial heart of Georgia, enables Russia to reach the capital Tbilisi very rapidly, to cut the country's main east-west communications corridor, and to neutralise the Baku-Tbilisi-Ceyhan oil pipeline, which supplies the world markets and passes south of the Georgian capital. [...] Russia's priority to break its encirclement by the Atlantic Alliance has been achieved." On 11 November 2008, Melik Kaylan wrote in Forbes: "There is an additional misconception that [...] the Bush administration encouraged Saakashvili to confront the Russians or at least bolstered his sense of allied support. This is manifestly untrue. Tbilisi insiders told me that Georgia had been asking the Bushies for anti-aircraft missiles for some years.
Nevertheless, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, the well-studied tumor suppressor that is better known as PTEN, gets its name from homology with PTPs and tensin 1. More detailed structure comparisons have revealed that tensins 1-3, PTEN, auxilin and other proteins in animals, plants and fungi comprise a PTP-C2 superdomain. An integrated PTP domain and C2 domain, the PTP-C2 superdomain came into existence over 1 billion years ago and has functioned as a single heritable unit since then. The first tensin cDNA sequence was isolated from chicken. Analysis of knockout mice has demonstrated critical roles of tensin in renal function, muscle regeneration, and cell migration. Evidence is now emerging to suggest tensin is an important component linking the ECM, the actin cytoskeleton, and signal transduction. Therefore, tensin and its downstream signaling molecules may be targets for therapeutic interventions in renal disease, wound healing and cancer.
== History == Epidemics of meningococcal A meningitis, which is a bacterial infection of the thin lining surrounding the brain and spinal cord, have swept across 26 countries in sub-Saharan Africa for a century, killing and disabling young people every year. The disease is highly feared on the continent; it can kill or cause severe brain damage in a child within hours. Epidemics usually start at the beginning of the calendar year when dry sands from the Sahara Desert begin blowing southward. The largest meningitis epidemic in African history swept across sub-Saharan Africa from 1996 to 1997, numbering 250,000 new cases and taking 25,000 lives. Three years later, the World Health Organization (WHO) held a technical consultation in Cairo, Egypt with African ministers of health and global health leaders to discuss meningitis and the development of a new vaccine. At that meeting, representatives from eight African countries issued a statement saying that the development of a meningococcal vaccine to prevent epidemics was a high priority for them, and concluded that a conjugate meningococcal vaccine would have the potential to prevent future epidemics. They estimated that the new vaccine could become available in three to seven years for US$0.40 to $1 a dose, providing protection for at least ten years. A year later, in 2001, the Bill & Melinda Gates Foundation provided a ten-year, $70 million grant to establish the Meningitis Vaccine Project, a partnership between PATH and WHO.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.